Not only is the CD20:rituximab complex removed from the cell surface and degraded in the lysosome, but FcγRIIB‐bound rituximab is also unable to interact in trans with activating Fc receptors on effector cells that mediate tumor cell killing [16]. Here, FCGR2B is linked to neoplasm.